Full Name
Adam Brufsky, MD, PhD
Speaker Bio
Adam M. Brufsky, MD, PhD is Professor of Medicine at the University of Pittsburgh and Co-Director of the Cancer Therapeutics Program at UPMC Hillman Cancer Center. Medical Director of the Women’s Cancer Center at UPMC Magee Women’s Hospital, he has published over 300 papers and leads multiple NIH- and foundation-funded breast cancer studies.
Speaking At
GS2-00 - Correlative Analysis of Overall Survival by Intrinsic Subtype Across the MONALEESA-2, -3, and -7 Studies of Ribociclib + Endocrine Therapy in Patients With HR+/HER2- Advanced Breast Cancer
GS2-04 - Aromatase inhibitors versus tamoxifen in pre-menopausal women with ER+ early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials
GS2-07 - RPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
GS4-10 - Neratinib + fulvestrant + trastuzumab for hormone-receptor positive, HER2-mutant metastatic breast cancer, and neratinib + trastuzumab for metastatic triple-negative disease: latest updates from the SUMMIT trial
GS2-01 - Trastuzumab deruxtecan vs physician's choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: Primary results of the randomized phase 3 study DESTINY-Breast02
GS2-02 - Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03
GS2-03 - TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan (T-DXd) with or without anastrozole for HER2-low, HR+ early-stage breast cancer
GS02-01 - Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01.
GS02-04 - Surgical treatment of women with breast cancer and a BRCA1 mutation: an international analysis of the impact of bilateral mastectomy on survival.
GS02-06 - Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial.
GS02-07 - Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304
GS02-08 - Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer
GS02-01 - Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01. (China)
GS02-04 - Surgical treatment of women with breast cancer and a BRCA1 mutation: an international analysis of the impact of bilateral mastectomy on survival. (China)
GS02-06 - Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial. (China)
GS02-07 - Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304 (China)
GS02-08 - Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer (China)
RF1-05: DNA methylation patterns are similar in benign tissue from ipsilateral and contralateral breast while different from matched breast cancer, and healthy controls.
RF1-06: Association of polygenic-based breast cancer risk prediction with patient management.
RF1-07: Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.
GS2-04 - Aromatase inhibitors versus tamoxifen in pre-menopausal women with ER+ early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials
GS2-07 - RPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
GS4-10 - Neratinib + fulvestrant + trastuzumab for hormone-receptor positive, HER2-mutant metastatic breast cancer, and neratinib + trastuzumab for metastatic triple-negative disease: latest updates from the SUMMIT trial
GS2-01 - Trastuzumab deruxtecan vs physician's choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: Primary results of the randomized phase 3 study DESTINY-Breast02
GS2-02 - Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03
GS2-03 - TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan (T-DXd) with or without anastrozole for HER2-low, HR+ early-stage breast cancer
GS02-01 - Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01.
GS02-04 - Surgical treatment of women with breast cancer and a BRCA1 mutation: an international analysis of the impact of bilateral mastectomy on survival.
GS02-06 - Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial.
GS02-07 - Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304
GS02-08 - Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer
GS02-01 - Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01. (China)
GS02-04 - Surgical treatment of women with breast cancer and a BRCA1 mutation: an international analysis of the impact of bilateral mastectomy on survival. (China)
GS02-06 - Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial. (China)
GS02-07 - Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304 (China)
GS02-08 - Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer (China)
RF1-05: DNA methylation patterns are similar in benign tissue from ipsilateral and contralateral breast while different from matched breast cancer, and healthy controls.
RF1-06: Association of polygenic-based breast cancer risk prediction with patient management.
RF1-07: Multifactor analysis for pathologic complete response (pCR) in a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab (DTP Trial) in HER2-enriched early breast cancer.
